News from csl A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 16, 2014, 13:24 ET

CSL St-Laurent Sets Sail on Maiden Voyage, Completing CSL's Trillium Class Newbuild Program

MONTREAL, Dec. 16, 2014 /CNW Telbec/ - The second of Canada Steamship Lines' (CSL) two newbuild Trillium Class Great Lakes bulk carriers, CSL...

Dec 16, 2014, 09:04 ET
CSL Behring logo.

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) for Hemophilia B Patients

CSL Behring Continues Improving Patient Well-Being; Key Milestone Achieved in PROLONG-9FP, Company's Recombinant Factor IX Fusion Protein...

Dec 04, 2014, 09:00 ET
CSL Behring logo.

CSL Issues "Our Corporate Responsibility 2014" Report

CSL Behring's parent company CSL Limited (ASX: CSL) has issued its annual corporate responsibility report – "Our Corporate Responsibility...

Dec 04, 2014, 06:00 ET

La EMA aprueba la ficha técnica enmendada de Hizentra® de CSL Behring

-- La nueva ficha técnica ofrece una mayor flexibilidad y capacidad para personalizar la dosificación CSL Behring ha...

Dec 04, 2014, 06:00 ET

EMA approva la revisione del Riassunto delle Caratteristiche del Prodotto (RCP) Hizentra® di CSL Behring

-- Il nuovo RCP favorisce maggiore flessibilità e capacità di personalizzare il dosaggio  CSL Behring ha annunciato...

Dec 04, 2014, 06:00 ET

EMA erteilt Zulassung für aktualisierte Produktinformation für Hizentra® von CSL Behring

-- Neue Produktinformation unterstützt größere Flexibilität und die Möglichkeit zur individuellen Dosierung...

Dec 01, 2014, 11:00 ET

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra®

CSL Behring today announced that the Centers for Medicare and Medicaid Services (CMS) has extended the new technology add-on payment...

Nov 18, 2014, 10:00 ET

CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated

Two research studies presented today at the American Heart Association Scientific Sessions in Chicago provide further understanding of the...

Nov 17, 2014, 13:18 ET

Neue Daten beim 16. Biennial Meeting der European Society for Immunodeficiencies (ESID) sprechen für individualisierte Dosierung von Hizentra®

-- Flexible Dosierungsschemata und Push-Applikation stehen im Fokus der Präsentationen  Das Behandlungsziel der...

Nov 12, 2014, 08:00 ET

CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque

 CSL Limited today announced the launch of AEGIS-I, a Phase 2b clinical study of CSL112, a novel formulation of apolipoprotein A-I (apoA-I)....

Nov 03, 2014, 15:29 ET

En la 16 Reunión Bienal de la Sociedad Europea para Inmunodeficiencias se respalda dosis individualizada con Hizentra®

- Evidencia presentada en la 16 Reunión Bienal de la Sociedad Europea para Inmunodeficiencias: (ESID) que respalda la dosis...

Nov 03, 2014, 14:27 ET

La testimonianza presentata al 16esimo Congresso Biennale della European Society for Immunodeficiencies (ESID) supporta il dosaggio individualizzato con Hizentra®

-- Le presentazioni pongono l'attenzione sui regimi di dosaggio flessibili di Hizentra e sulla modalità di somministrazione push...

Oct 31, 2014, 08:30 ET
CSL Behring logo

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized Dosing with Hizentra®

The goal of individualized therapy in the treatment of primary immunodeficiency (PI), a serious, life-threatening and lifelong condition, is to...

Oct 29, 2014, 11:57 ET

CSL Behring signe un accord de développement stratégique auprès d'Enable Injections afin de commercialiser un tout nouveau dispositif de délivrance médicamenteuse

CSL Behring a annoncé aujourd'hui que sa filiale CSL Behring AG, basée à Berne, en Suisse, et Enable Injections, LLC, basée...

Oct 29, 2014, 10:02 ET

CSL Behring y Enable Injections lanzan un nuevo dispositivo de administración de medicamento

-- CSL Behring firma un acuerdo de desarrollo estratégico con Enable Injections para comercializar un nuevo dispositivo de...

Oct 29, 2014, 10:00 ET
Professional golfer Perry Parker with this year's golf winner and alumni from the program

CSL Behring Announces Winners of its 13th Annual Gettin' in the Game(SM) Junior National Championship Program

 CSL Behring announced that William McCarthy from the Western Pennsylvania Chapter of the National Hemophilia Foundation and Nicholas Cleghorn...

Oct 29, 2014, 07:07 ET

CSL Behring unterzeichnet strategische Entwicklungsvereinbarung mit Enable Injections zur Vermarktung eines neuartigen Arzneimittel-Verabreichungsgeräts

CSL Behring hat heute bekanntgegeben, dass sein angeschlossenes Unternehmen, die CSL Behring AG aus Bern, Schweiz, und Enable Injections, LLC, aus...

Oct 28, 2014, 11:10 ET
CSL Behring logo

CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL Behring announced today that its affiliate company, CSL Behring AG, of Bern, Switzerland and Enable Injections, LLC, of Franklin, Ohio have...

Oct 27, 2014, 08:20 ET

CSL to acquire Novartis' influenza vaccine business

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has agreed to acquire Novartis' global influenza vaccine business for US$275 million....

Oct 13, 2014, 09:00 ET
CSL Behring logo. (PRNewsFoto/CSL Behring)

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

CSL Behring and its subsidiary, CSL Plasma, join the Plasma Protein Therapeutics Association (PPTA) in saluting the contributions of plasma donors...